Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Saudi - Delayed Quote SAR

Mouwasat Medical Services Company (4002.SR)

Compare
73.40
+0.60
+(0.82%)
At close: April 14 at 3:19:37 PM GMT+3
Loading Chart for 4002.SR
  • Previous Close 72.80
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 144.00
  • Volume 0
  • Avg. Volume 678,596
  • Market Cap (intraday) 14.68B
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) 22.72
  • EPS (TTM) 3.23
  • Earnings Date May 12, 2025 - May 16, 2025
  • Forward Dividend & Yield 2.00 (2.75%)
  • Ex-Dividend Date May 6, 2025
  • 1y Target Est 102.47

Mouwasat Medical Services Company, together with its subsidiaries, engages in the acquisition, management, operation, and maintenance of hospitals, medical centers, drug stores, and pharmacies in the Kingdom of Saudi Arabia. The company operates a network of hospitals that provides medical services; and specialized centers, including eye, long term, rehabilitation, and cardiology centers, as well as stroke unit, nuclear medicine, fertility, diabetes and diabetic foot, skin care, and badana clinic. It also provides various services comprising inpatient pharmacy services, TPN and IV medication preparation units, chemotherapy medication preparation, anti-coagulant clinic, and clinical pharmacy services. In addition, the company is involved in construction and operation of hospitals, dispensaries, and special clinics; general construction of non-residential buildings including schools, hospitals, and hotels; demolition of buildings; purchase, sale, and division of land and real estate, and off-plan sales activities; operation of colleges and university institutes; and medical operation activities. Further, it wholesales medical equipment and drugs. Mouwasat Medical Services Company was founded in 1974 and is based in Dammam, the Kingdom of Saudi Arabia.

www.mouwasat.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 4002.SR

View More

Performance Overview: 4002.SR

Trailing total returns as of 4/14/2025, which may include dividends or other distributions. Benchmark is Tadawul All Shares Index (^TASI.SR) .

YTD Return

4002.SR
13.75%
Tadawul All Shares Index (^TASI.SR)
3.65%

1-Year Return

4002.SR
0.00%
Tadawul All Shares Index (^TASI.SR)
8.44%

3-Year Return

4002.SR
34.92%
Tadawul All Shares Index (^TASI.SR)
14.86%

5-Year Return

4002.SR
99.93%
Tadawul All Shares Index (^TASI.SR)
68.70%

Compare To: 4002.SR

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 4002.SR

View More

Valuation Measures

Annual
As of 4/14/2025
  • Market Cap

    14.68B

  • Enterprise Value

    14.93B

  • Trailing P/E

    22.72

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    5.10

  • Price/Book (mrq)

    4.11

  • Enterprise Value/Revenue

    5.19

  • Enterprise Value/EBITDA

    15.32

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    22.43%

  • Return on Assets (ttm)

    8.72%

  • Return on Equity (ttm)

    18.75%

  • Revenue (ttm)

    2.88B

  • Net Income Avi to Common (ttm)

    645.76M

  • Diluted EPS (ttm)

    3.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    511.57M

  • Total Debt/Equity (mrq)

    20.51%

  • Levered Free Cash Flow (ttm)

    602.11M

Research Analysis: 4002.SR

View More

Company Insights: 4002.SR

Research Reports: 4002.SR

View More

People Also Watch